We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » GSK’s Heart Drug Darapladib Fails Again in Phase III
The item has been added to your shopping cart.
GSK’s Heart Drug Darapladib Fails Again in Phase III
UK drug giant GlaxoSmithKline said Tuesday that its investigational coronary drug darapladib failed to reduce cardiovascular events in patients experiencing symptoms of obstructed blood flow to the heart, marking another setback for the once promising therapy.